Digoxin-specific antibody fragments: How much and when?

Toxicological Reviews

Volumn 23, Issue 3, 2004, Pages 135-143

  Bateman, D Nicholas ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITALIS GLYCOSIDE; DIGITOXIN; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; NEUTRALIZING ANTIBODY; POTASSIUM;

BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DIGITALIS INTOXICATION; DOSE CALCULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG OVERDOSE; DRUG POTENCY; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; HEART ARRHYTHMIA; HEART BLOCK; HUMAN; HYPERKALEMIA; NAUSEA; PLASMA HALF LIFE; PLASMA PROTEIN BINDING; POTASSIUM BLOOD LEVEL; PSYCHOSIS; REVERSAL REACTION; REVIEW; RHEUMATIC HEART DISEASE; SEIZURE; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; URINARY EXCRETION; VOMITING;

DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POISONING;

EID: 17544362782     PISSN: 11762551     EISSN: None     Source Type: Journal    
DOI: 10.2165/00139709-200423030-00001     Document Type: Review

References (14)

1. Withering W. An account of the foxglove and some of its medical uses: with practical remarks on dropsy and other diseases. London: J and J Robinson, 1785.
2. Eddleston M, Rajapakse S, Rajakanthan Jayalath S, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet 2000; 355: 967-72
3. Gowda RM, Cohen RA, Khan IA. Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. Heart 2003; 89: e14
4. Dollery C, editor. Therapeutic drugs. 2nd ed. London: Churchill Livingstone, 1998: D123-D130
5. Smith TW, Haber E, Yeatman L, et al. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294: 797-800
6. Antman EM, Wenger TL, Butler VP, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Circulation 1990; 81: 1744-52
7. Ujhelyi MR, Robert S. Pharmacological aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; 28: 483-93
8. Wenger TL, Butler VP, Haber E, et al. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J Am Coll Cardiol 1985; 5: 118A-23A
9. Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17: 590-8
10. Woolf AD, Wenger T, Smith TW, et al. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med 1992; 326: 1739-44
11. Smolarz A, Roesch E, Lenz E, et al. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol 1985; 23: 327-40
12. Taboulet P, Baud FJ, Bismuth C, et al. Acute digitalis intoxication: is pacing still appropriate? J Toxicol Clin Toxicol 1993; 31: 261-73
13. Schaumann W, Kaufmann B, Neubert P, et al. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 1986; 30: 527-33
14. Lavaux T, Assemi P, Casset A, et al. Efficiency of a non-equimolar neutralisation of digoxin by immune Fab therapy. J Toxicol Clin Toxicol 2004; 42: 464-5